A securities class action has been filed against Spectrum Pharmaceuticals, Inc. (SPPI) on behalf of shareholders who purchased the Company’s securities between December 27, 2018 through August 5, 2021. This case has been filed in the USDC – NV.
According to the Complaint, the Company made false and misleading statements to the market. Spectrum’s manufacturing facility for ROLONTIS failed to maintain appropriate controls and procedures. These deficiencies diminished the likelihood of the Company’s Biologics License Application (BLA) for ROLONTIS receiving FDA approval. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Spectrum, investors suffered damages.